Matthew R. Groves received his Honours Degree in Physics from Worcester College, Oxford University, and gained his PhD from the University of London in 1999 under the supervision of Prof Tom Blundell. After post-doctoral experience in Oxford and EMBL, Heidelberg. He was appointed as an independent staff scientist at EMBL Hamburg. In 2013, he moved to the Groningen Research Institute for Pharmacy, University of Groningen and is now an associate professor. He is currently responsible for the "Medicinal Chemistry and Biophysics" course and is also involved in a Masters's program in "Molecular Medicines and Innovative Therapies" as a lecturer. His teaching disciplines include crystallography, biophysics, and infectious diseases. His research interests include structure-based drug design in human diseases, using structural, biochemical, and molecular biology to investigate disease-relevant pathways in cancer, malaria, and tuberculosis.
Research Keywords & Expertise
Biophysics
Drug Design
Infectious Diseases
Structural Biology
Biocrystallogenesis
Fingerprints
11%
Biophysics
6%
Drug Design
5%
Infectious Diseases
5%
Structural Biology
Short Biography
Matthew R. Groves received his Honours Degree in Physics from Worcester College, Oxford University, and gained his PhD from the University of London in 1999 under the supervision of Prof Tom Blundell. After post-doctoral experience in Oxford and EMBL, Heidelberg. He was appointed as an independent staff scientist at EMBL Hamburg. In 2013, he moved to the Groningen Research Institute for Pharmacy, University of Groningen and is now an associate professor. He is currently responsible for the "Medicinal Chemistry and Biophysics" course and is also involved in a Masters's program in "Molecular Medicines and Innovative Therapies" as a lecturer. His teaching disciplines include crystallography, biophysics, and infectious diseases. His research interests include structure-based drug design in human diseases, using structural, biochemical, and molecular biology to investigate disease-relevant pathways in cancer, malaria, and tuberculosis.